Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22;9(10):e0017124.
doi: 10.1128/msystems.00171-24. Epub 2024 Sep 4.

Metapopulation model of phage therapy of an acute Pseudomonas aeruginosa lung infection

Affiliations

Metapopulation model of phage therapy of an acute Pseudomonas aeruginosa lung infection

Rogelio A Rodriguez-Gonzalez et al. mSystems. .

Abstract

Infections caused by multidrug resistant (MDR) pathogenic bacteria are a global health threat. Bacteriophages ("phage") are increasingly used as alternative or last-resort therapeutics to treat patients infected by MDR bacteria. However, the therapeutic outcomes of phage therapy may be limited by the emergence of phage resistance during treatment and/or by physical constraints that impede phage-bacteria interactions in vivo. In this work, we evaluate the role of lung spatial structure on the efficacy of phage therapy for Pseudomonas aeruginosa infections. To do so, we developed a spatially structured metapopulation network model based on the geometry of the bronchial tree, including host innate immune responses and the emergence of phage-resistant bacterial mutants. We model the ecological interactions between bacteria, phage, and the host innate immune system at the airway (node) level. The model predicts the synergistic elimination of a P. aeruginosa infection due to the combined effects of phage and neutrophils, given the sufficient innate immune activity and efficient phage-induced lysis. The metapopulation model simulations also predict that MDR bacteria are cleared faster at distal nodes of the bronchial tree. Notably, image analysis of lung tissue time series from wild-type and lymphocyte-depleted mice revealed a concordant, statistically significant pattern: infection intensity cleared in the bottom before the top of the lungs. Overall, the combined use of simulations and image analysis of in vivo experiments further supports the use of phage therapy for treating acute lung infections caused by P. aeruginosa, while highlighting potential limits to therapy in a spatially structured environment given impaired innate immune responses and/or inefficient phage-induced lysis.

Importance: Phage therapy is increasingly employed as a compassionate treatment for severe infections caused by multidrug-resistant (MDR) bacteria. However, the mixed outcomes observed in larger clinical studies highlight a gap in understanding when phage therapy succeeds or fails. Previous research from our team, using in vivo experiments and single-compartment mathematical models, demonstrated the synergistic clearance of acute P. aeruginosa pneumonia by phage and neutrophils despite the emergence of phage-resistant bacteria. In fact, the lung environment is highly structured, prompting the question of whether immunophage synergy explains the curative treatment of P. aeruginosa when incorporating realistic physical connectivity. To address this, we developed a metapopulation network model mimicking the lung branching structure to assess phage therapy efficacy for MDR P. aeruginosa pneumonia. The model predicts the synergistic elimination of P. aeruginosa by phage and neutrophils but emphasizes potential challenges in spatially structured environments, suggesting that higher innate immune levels may be required for successful bacterial clearance. Model simulations reveal a spatial pattern in pathogen clearance where P. aeruginosa are cleared faster at distal nodes of the bronchial tree than in primary nodes. Interestingly, image analysis of infected mice reveals a concordant and statistically significant pattern: infection intensity clears in the bottom before the top of the lungs. The combined use of modeling and image analysis supports the application of phage therapy for acute P. aeruginosa pneumonia while emphasizing potential challenges to curative success in spatially structured in vivo environments, including impaired innate immune responses and reduced phage efficacy.

Keywords: Pseudomonas aeruginosa; antibiotic resistance; antimicrobial agents; bacteriophage therapy; infectious disease; innate immunity; lung infection; mathematical modeling; microbial ecology; virology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Schematic of the metapopulation network model of phage therapy of a P. aeruginosa infection. The structure of the metapopulation network is based on the geometry of a symmetrical bronchial tree with a dichotomous branching pattern (a). The airways of the bronchial tree (left) are represented by the network nodes (a-middle), while the network links represent the branching points of the bronchial tree. For example, the section that connects the trachea to the left and right main bronchi is considered a branching point. We assume that the bronchial tree is symmetrical such that the left and right parts of the tree are identical and so are their dynamics in a deterministic system. Therefore, we only focus on one side of the tree (the dashed line on the middle network) and reduce the number of nodes in our original network to one node per generation. The final network topology of this reduced model consists of 15 connected nodes that form a chain (right). The degree of the network nodes is 4, except for the first and last nodes, which have a degree of 2. In panel b, we show the ecological interactions between phage-susceptible bacteria (BS), phage-resistant bacteria (BR), phage (P), and the host innate immune response (I) at the node level (left). Phage infects the susceptible strain, while the resistant strain is _targeted only by the innate immune response. The immune response grows in the presence of bacteria and _targets both bacterial strains. Neutrophils are recruited to the site of the infection from the pulmonary vasculature, while phage and bacteria transfer between connected nodes to spread across the network (right).
Fig 2
Fig 2
Spatiotemporal dynamics of phage therapy of a P. aeruginosa lung infection. Population dynamics at the node level for phage (solid yellow line), phage-susceptible bacteria (solid blue line), phage-resistant bacteria (solid orange line), and the host innate immune response (purple solid line). We set the lower bound of the y-axis for each node panel to the 1/Vi density level, such that only densities corresponding to species numbers >1 CFU (PFU or cell) are depicted, where Vi is the volume of node i. Simulation configuration is provided in the main text with parameter values in Table 1 and computational details in Text S1.
Fig 3
Fig 3
Bacterial dynamics under different phage and innate immune treatments. We simulate four treatment scenarios that result from the presence or absence of both phage and the innate immune response. We show the bacterial dynamics across the metapopulation network when the host is immunodeficient untreated (a) or phage-treated (c). Similarly, we show the bacterial dynamics when the host is immunocompetent untreated (b) or phage-treated (d). The heatmaps depict the progression of the bacterial infection across the network; each row represents a network node, g, while the columns indicate the simulation time (hour). The node color represents the bacterial density at a given time. The yellow regions represent high bacterial density, and the white areas represent infection clearance. When the host is immunocompetent and phage-treated, we zoom in and show the infection clearance pattern (e). Effects of varying the mucin level (1%–4%) on the infection clearance time (f). On the heatmaps, row 1 represents Generation 1 and the top of the lungs, while row 15 represents Generation 15 and the bottom of the lungs. The simulation configuration is provided in the main text with parameter values in Table 1 and computational details in Text S1.
Fig 4
Fig 4
Infection elimination time given variations in the distribution of the phage dose and bacterial inoculum in the bronchial network. We evaluate different forms of allocating the bacterial inoculum (B0) and the phage dose (P0) among network nodes and calculate the infection clearance time at the node level (g). Distributions include (a) uniform distribution of the bacterial inoculum among all network nodes; (b) distribution of the bacterial inoculum between the first three nodes (c), among the last 12 nodes of the network, or (d) exclusively within the first node of the network. We use the same distribution forms as the bacterial inoculum for the phage dose (different markers inside plots). The simulation configuration is provided in the main text with parameter values in Table 1 and computational details in Text S1.
Fig 5
Fig 5
Probability of therapeutic success given intermediate phage efficacy and host innate immune levels. The probability of therapeutic success is examined given the variation in the percentage of neutrophils available (x-axis, from 1% to 100%) and phage adsorption rate (y-axis, from 109 to 106 (ml/PFU)σh1). Therapeutic success is measured based on 84 different initial distributions of the phage and bacterial inoculum. The colored regions represent a p>0 of clearing the infection, while black regions represent failure to clear the infection, i.e., a p=0 of therapeutic success. The white solid line contours the region of infection clearance predicted by the well-mixed model. The simulation configuration is provided in the main text with parameter values in Table 1 and computational details in Text S1. Here, mucin is set to a 2.5% level.
Fig 6
Fig 6
In vivo P. aeruginosa murine pneumonia data. Images depict infection dynamics of P. aeruginosa strain PAKlumi in vivo during 72 hours. Data are for two mice groups, WT (N = 4; mouse #1 to 4) and Rag2/Il2rg/ (N = 9; mouse #5 to 13). The bioluminescence signal represents the intensity of the infection in different mouse regions—a proxy for bacterial densities. A pixel intensity of 1 represents the highest bacterial density, while 0 represents the limit of detection. The white dashed line separates the upper and lower compartments of the mouse respiratory system. The orange and green boxes highlight the approximate time when the total intensity signal drops below the intensity threshold in the lower and upper compartments, respectively. Mice were inoculated with 107 P. aeruginosa cells, and 2 hours after the bacterial inoculation, mice were treated with phage PAK_P1 (108 PFU).
Fig 7
Fig 7
Time series of the total intensity signal and the infection clearance analysis using in vivo P. aeruginosa murine pneumonia data. We show the time series of total intensity signals for the upper and lower compartments of 13 mice (a). The total intensity of one compartment is calculated by adding the pixel intensity values from all pixels making up a compartment. The black dashed line represents the intensity threshold (value of 3) below which the total intensity signal clears. We calculate the time to infection resolution for the upper and lower compartments (b). We use data from 13 mice, including WT (N = 4) and Rag2/Il2rg/ (N = 9) mice groups. We used the one-sided Wilcoxon signed rank test to compare the infection clearance time difference between the upper and lower compartments (b).

Update of

Similar articles

Cited by

References

    1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. . 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629–655. doi:10.1016/S0140-6736(21)02724-0 - DOI - PMC - PubMed
    1. World Health Organization . 2022. 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization.
    1. Pallavali RR, Degati VL, Lomada D, Reddy MC, Durbaka VRP. 2017. Isolation and in vitro evaluation of bacteriophages against MDR-bacterial isolates from septic wound infections. PLoS One 12:e0179245. doi:10.1371/journal.pone.0179245 - DOI - PMC - PubMed
    1. Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H. 2004. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 48:2558–2569. doi:10.1128/AAC.48.7.2558-2569.2004 - DOI - PMC - PubMed
    1. El-Atrees DM, El-Kased RF, Abbas AM, Yassien MA. 2022. Characterization and anti-biofilm activity of bacteriophages against urinary tract enterococcus faecalis isolates. Sci Rep 12:13048. doi:10.1038/s41598-022-17275-z - DOI - PMC - PubMed

LinkOut - more resources

  NODES
twitter 2